The ADVOCATE trial, sponsored by ChemoCentryx, assessed the safety of CCX168(avacopan) in inducing and sustaining remission in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). To everyone’s surprise a set of conclusive findings...